Reduce bloating and excess gas with a common antibiotic

In the first study of its kind, researchers discovered that rifaximin, an antibiotic used to treat diarrhea, is an effective treatment for abdominal bloating and flatulence, including in irritable bowel syndrome (IBS) patients. This research is published in the February issue of The American Journal of Gastroenterology.

In this randomized double-blind placebo-controlled trial, researchers at the American University of Beirut in Lebanon treated 124 patients with rifaximin therapy and found that it was effective at relieving the symptoms of bloating and excess gaseousness by way of reducing the amount of hydrogen gas produced in the large intestine. And because rifaximin is non-absorbable, there are no side effects, making it suitable for chronic use.

Research has shown that these symptoms are common and often more disturbing to IBS patients, as well as being harder to treat, than the commonly associated diarrhea and constipation. Fortunately, among the patients with IBS in the trial, a favorable response was also noted, which lasted even through the post-treatment phase of the study.


Contact: Sharon Agsalda
Blackwell Publishing Ltd.

Page: 1

Related medicine news :

1. Reduced greenhouse gas emissions required to avoid dangerous increases in heat stress
2. Reduced dietary fat intake may decrease breast cancer recurrence
3. Reduced antibiotic prescribing is associated with increased hospital admissions
4. Reduced insulin in the brain triggers Alzheimers degeneration
5. Reduced brain volume may predict dementia in healthy elderly people
6. Depressed patients experience excessive inflammation during stressful situations
7. Parkinsons medication appears to trigger excessive gambling
8. Refusal of medical and surgical interventions common among chronically ill elderly
9. Needle-stick injuries are common but unreported by surgeons in training
10. Sleep-related breathing disorder common among aggressive, bullying schoolchildren
11. Nearly half of children in Kenya with common type of severe malaria affected neurologically

Post Your Comments:

(Date:11/25/2015)... , ... November 25, 2015 , ... ... physicians and athletic programs, launches new Wimbledon Athletics Facebook page to ... young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... double board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, ... The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... “While riding ... an inventor, from Bronx, N.Y. “I thought there had to be a convenient and ... the PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or ...
(Date:11/25/2015)... ... 2015 , ... "When I underwent breast reconstruction following a ... said an inventor from Bronx, N.Y. "In order to meet my own individual ... for added comfort and support. The bra is easier to put on and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization ... well as raising public awareness of the disorder while helping to bring expert ... of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at Ann ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... MELVILLE, N.Y. , Nov. 25, 2015  Henry ... products and services to office-based dental, medical and animal ... Dental (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion ... industry,s broadest array of open solutions designed to help ... Click here for a schedule of ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... with the New York State Attorney ... the Sherman Act, and other statutes with the Attorney General ... 2014, to cease marketing and selling the now generic version ... Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology:
Cached News: